Our results provide a strategy of abolishing the “immune barrier” of PD‐L1 on VECs and further maintaining PD‐L1 expression on tumor cells to be sensitive to PD‐L1 antibody to reinforce the immunotherapeutic efficacy.9 Here, CD274 is linked to neoplasm.